培美曲塞对化疗及靶向治疗失败的晚期肺腺癌的疗效观察

Clinical Efficacy of Pemetrexed for Advanced Lung Adenocarcinoma Failed Chemotherapy and Targeted Therapy

目的探讨培美曲塞对化疗及靶向治疗失败的晚期肺腺癌的治疗价值。方法随机抽取2012年8月至2014年8月54例晚期肺腺癌患者的临床资料。按照临床治疗方法将患者分为实验组(28例)和对照组(26例)。实验组采用培美曲塞单药化疗,对照组患者经常规治疗无效后采取其他化疗方案、支持治疗等措施。观察患者临床疗效、不良反应发生情况、生活质量变化情况。结果实验组近期疗效优于对照组,差异有统计学意义(P<0.05)。实验组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。实验组患者QOL总评分高于对照组,差异具有统计学意义(P<0.05)。结论培美曲塞治疗化疗及靶向治疗失败的晚期肺腺癌,可有效提高临床疗效,降低不良反应发生情况,改善患者生活质量。

Objective To explore the clinical efficacy of pemetrexed for advanced lung adenoearcinoma failed chemo-therapy and targeted therapy. Methods 54 cases of advanced lung adenocarcinoma were divided into the experiment group （ 28 cases） and the control group （26 cases ）. The experiment group were treated by pemetrexed, the control group were treated by oth- er methods. The clinical effects, side effects, QOL of the 2 groups were compared. Results The clinical effects of the experiment group was higher than that of the control group（P 〈 0.05 ） ;The side effects of the experiment group were lower than that of the control group（ P 〈 0.05 ） ; The scores of QOL of the experiment group were higher than that of the control group（ P 〈 0.05 ）. Conclusion Pemetrexed for advanced lung adenocarcinoma failed chemotherapy and targeted therapy can improve clinical efficacy, reduce side effect, and improve quality of life.